Congenital Myasthenic Syndromes

Congenital myasthenic syndromes are rare disorders that affect muscles from birth. They are caused by problems with the nerves or muscles themselves, not by the immune system attacking them. These problems can happen at different points where nerves meet muscles. The most common cause is a change in the genes that control the proteins in the nerve endings, which are needed to send signals to the muscles.

Condition

What people with Congenital Myasthenic Syndromes report

Every report comes from a Lived member, sent anonymously.

Have you tried Mestinon (Pyridostigmine) for Congenital Myasthenic Syndromes?

NameHow it went

About Congenital Myasthenic Syndromes

What It Is

Congenital myasthenic syndromes (CMS) are a group of rare inherited conditions in which signals do not pass properly from nerves to muscles. The result is muscle weakness that gets worse with use and improves with rest. Symptoms usually start at birth or in early childhood, although some forms are not recognized until adolescence or adulthood. The muscles most often affected control the eyelids and eye movements, chewing, swallowing, speech and facial expression, along with the arms and legs. Babies may feed poorly, have a weak cry or have brief pauses in breathing. Children may reach milestones such as sitting and walking later than usual. Severity ranges widely, from mild weakness to disability that requires a wheelchair or breathing support. CMS can look like myasthenia gravis, which also causes fatigable weakness. The difference matters: myasthenia gravis is an autoimmune disease in which the immune system blocks the nerve-muscle signal, while CMS comes from a gene change that alters the nerve-muscle connection itself. Immune treatments that help myasthenia gravis do not help CMS. CMS is uncommon, estimated at about 2 in a million people overall and about 10 in a million children.

Causes & Risk Factors

CMS is caused by changes (variants) in one of more than 35 genes, each needed for the nerve-muscle junction to work. That junction is the small gap where a nerve releases a chemical messenger, acetylcholine, and the muscle responds by contracting. Depending on the gene, the problem can lie in the nerve ending, in the gap between nerve and muscle, or in the muscle's receptors for acetylcholine. Variants in the CHRNE gene, which affects the acetylcholine receptor, account for the largest share of cases. Most forms are autosomal recessive: a child is affected when both parents pass on a variant, and the parents usually have no symptoms themselves. Some forms, such as slow-channel CMS, are autosomal dominant, so one affected parent can pass the condition on. In some people the responsible gene is not found. The genetic cause is present from birth, but day-to-day symptoms can be triggered or worsened by fever, infection, strenuous exertion and emotional stress. Pregnancy and puberty can also bring periods of worsening.

How It's Diagnosed

CMS is suspected when someone has weakness that worsens with activity, beginning in infancy or childhood, especially if relatives are affected. A neurologist, often one who specializes in neuromuscular conditions, takes a detailed history and examines which muscles are weak and how quickly they tire. Blood tests look for the antibodies that cause myasthenia gravis. In CMS these are usually absent, and that absence, together with a lack of response to immune treatment, points away from the autoimmune disease. Nerve tests then show whether the nerve-muscle signal is failing. In repetitive nerve stimulation, a nerve is stimulated several times in a row; a drop in the muscle's response of more than 10% suggests a transmission problem. Single-fiber electromyography (EMG), which records individual muscle fibers through a fine needle, can detect subtler signal delays. Genetic testing is the most important step. It usually uses a panel of known CMS genes or broader sequencing, and it confirms the diagnosis and identifies the subtype. The subtype matters because it guides which medicines are likely to help and which could make weakness worse. Breathing tests and sleep studies may also be done to check how well the breathing muscles work, including at night.

Treatment Options

There is no cure for CMS, but most forms improve with medicines that strengthen the nerve-muscle signal. The right choice depends on the genetic subtype, and a medicine that helps one form can harm another. Most of this knowledge comes from case reports and small groups of patients rather than large clinical trials, so treatment is adjusted carefully according to how each person responds. Pyridostigmine (Mestinon) is the most commonly used medicine. It slows the breakdown of acetylcholine so more of it is available to stimulate the muscle, and it helps many subtypes. In others, including slow-channel CMS and forms caused by the COLQ, DOK7, MUSK, LAMB2 or LRP4 genes (names a genetic test report would show), it can make weakness worse. Amifampridine (Firdapse), which increases acetylcholine release from the nerve, is approved in the US for a different nerve-muscle disorder (Lambert-Eaton myasthenic syndrome) and is sometimes added for CMS; like pyridostigmine, it can make some subtypes worse. For COLQ- and DOK7-related CMS, albuterol (called salbutamol outside the US, and better known as an asthma medicine) or ephedrine, both of which stimulate adrenaline-type receptors, is usually preferred. In slow-channel CMS, fluoxetine, an antidepressant, has been reported to reduce weakness. Support beyond medicine is a large part of care. Physical, occupational and speech therapy help with strength, daily tasks, speech and safe swallowing. Braces, walkers or a wheelchair can protect mobility. Some people use a breathing machine with a mask (noninvasive ventilation) at night or during the day, and a feeding tube may be needed when swallowing is unsafe or weight gain is poor. Surgery can correct severe curvature of the spine or foot deformities.

What to Expect

The course varies a great deal between subtypes and even within one family. Some forms stay stable or improve over childhood, some fluctuate, and some slowly progress. Many people with CMS attend school, work and live independently once they are on a treatment that suits their subtype, while others need ongoing help with mobility, feeding or breathing. DOK7-related CMS often causes weakness of the hip and shoulder muscles that can progress: in one study of 79 people with CMS, 6 of the 8 who used a wheelchair and needed breathing support had DOK7 variants. Albuterol has kept this weakness from progressing in some individual patients. Daily life often involves pacing activity, since weakness builds with use and recovers with rest. Fever, infection and emotional stress can bring sudden setbacks, so prompt treatment of infections matters, and a care plan for illness may include adjusting medicines. Some subtypes, particularly those affecting the nerve ending, carry a risk of sudden episodes of stopped breathing during illness, so the care team may advise closer watching during illnesses and include in the illness plan when to call for help. Follow-up with a neuromuscular specialist tracks strength, swallowing and breathing over time. Pregnancy can worsen symptoms, usually returning to the previous level within about six months after delivery, so close neurological monitoring during pregnancy is advised. Because CMS is inherited, genetic counseling can help relatives understand their own chances of carrying or passing on a variant. Before surgery, tell the care team about the diagnosis, since anesthesia can increase weakness in some people.

When to Seek Help

Arrange a medical evaluation if an infant or child has drooping eyelids, weak feeding or crying, delayed motor milestones, or weakness that clearly gets worse with activity, or if an adult has long-standing fatigable weakness with negative myasthenia gravis antibody tests. For someone already diagnosed, contact the care team promptly if a fever or infection brings increasing weakness, new trouble swallowing or choking, or if weakness gets worse after a medicine is started or changed. Get urgent medical care the same day if breathing becomes faster, shallower or more effortful, or a cough or cry becomes too weak to clear mucus, especially during an illness. Call 911 if someone stops breathing, turns blue around the lips or face, or has sudden, severe difficulty breathing.

Questions to Ask Your Doctor

  1. 1.Which gene is responsible for this form of CMS, and what does that mean for treatment?
  2. 2.Which medicines are likely to help this subtype, and are there any that could make it worse?
  3. 3.What should we do when fever or infection makes symptoms worse, and should we have a written plan for illness?
  4. 4.How will breathing and swallowing be monitored over time?
  5. 5.Should other family members have genetic testing or counseling?

Last reviewed • Oct 2026

Educational content, not medical advice.